U073 Off-label Use of Biologics and New Medications
DESCRIPTION
During the session, off-label use of biologic and other specialty drugs will be reviewed. The aim is to help the practioner optimize the delivery of appropriate treatments for patients. Medications to be discussed include TNF-alpha inhibitors, anti-IL17 antibodies, anti-IL23 biologics, dupilumab, apremilast, and JAK inhibitors.
This activity has been approved by the American Board of Dermatology (ABD) for up to 10 CCP Component 2 Self-Assessment points. For more information about CCP, please visit the ABD website at www.abderm.org.
LEARNING OBJECTIVES
Use dupilumab for bullous pemphigoid.
Use apremilast for seborrheic dermatitis and lichen planus.
Discuss the use of anti-IL17 and anti-IL23 biologics for hidradenitis suppurativa.
SCHEDULE
4:30 PM
Off-label Use of Biologics and New Medications
DIRECTOR
David Rosmarin, MD, FAAD
SPEAKERS
Edita Newton, PhD, MD, FAAD
Jay Wolverton, MD, FAAD
DISCLOSURES
Edita Newton, PhD, MD, FAAD
No financial relationships exist with ineligible companies.
David Rosmarin, MD, FAAD
AbbVie – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Abcuro, Inc. – Consultant(Honoraria); ability Biologics – Consultant (1099 relationship)(Honoraria); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Honoraria); Almirall – Consultant (1099 relationship)(Honoraria); AltruBio Inc. – Consultant(Honoraria); Amgen – Consultant (1099 relationship)(Grants/Research Funding), Other(Grants/Research Funding); Arena Pharmaceuticals – Consultant (1099 relationship)(Honoraria); Astria Therapeutics – Consultant (1099 relationship)(Honoraria); Boehringer Ingelheim – Advisory Board(Honoraria); Bristol-Myers Squibb – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Celgene – Investigator(Grants/Research Funding); Celgene Corporation – Advisory Board(Honoraria); Concert Pharmaceuticals – Consultant(Honoraria), Data Safety Monitoring Board(Honoraria); CSL Behring – Consultant(Honoraria); Dermavant Sciences – Advisory Board(Honoraria), Speaker(Honoraria); Dermira – Consultant(Honoraria); Dualitas Therapeutics – Consultant (1099 relationship)(Honoraria); Edesa Biotech – Consultant (1099 relationship)(Honoraria); EMD Serono – Consultant (1099 relationship)(Honoraria); First Tracks Biotherapeutics – Consultant (1099 relationship)(Honoraria); Forte Biosciences – Consultant (1099 relationship)(Honoraria); Imagene Bio – Consultant (1099 relationship)(Honoraria); Incyte Corporation – Consultant(Honoraria), Investigator(Grants/Research Funding); Janssen Biotech – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Kymera Therapeutics – Investigator(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – Consultant(Honoraria); Lilly ICOS LLC – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Merck & Co., Inc – Investigator(Grants/Research Funding); Nektar Therapeutics – Consultant (1099 relationship)(Honoraria); Novartis – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Phothera – Consultant (1099 relationship)(Honoraria); RAPT Therapeutics – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Recludix Pharma – Consultant (1099 relationship)(Honoraria); Regeneron – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Revolo Therapeutics – Consultant(Honoraria); Sanofi – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant(Honoraria), Data Safety Monitoring Board(Honoraria); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Honoraria); Triveni Bio – Data Safety Monitoring Board(Honoraria); UCB – Advisory Board(Honoraria); Viela Bio – Advisory Board(Honoraria); Zura Bio – Consultant (1099 relationship)(Honoraria);
Jay Wolverton, MD, FAAD
No financial relationships exist with ineligible companies.